Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy

Table 1 Patients’ characteristics

	Monotherapy	Boost	Total	p value
	(n = 155)	(n = 63)	(n = 218)	p value
Age (year)
mean ± SD	68.1 ± 6.6	70.3 ± 6.2	68.7 ± 6.5	0.023 ^§
PSA at diagnosis (ng/mL)
mean ± SD	7.2 ± 2.4	12.5 ± 6.1	8.7 ± 4.5	< 0.001 ^§
10 or less	139	22	161
10-20	16	34	50
greater than 20	0	7	7	< 0.001 ^※
biopsy Gleason score
6 or less	111	22	133
7	44	32	76
8-10	0	9	9	< 0.001 ^※
clinical T stage
T1c	99	32	131
T2a	51	19	70
T2b	5	6	11
T2c	0	6	6	< 0.001 ^※
neoadjuvant/adjuvant ADT
none	112	37	149
neoadjuvant (+)	42	18	60
adjuvant (+)	0	5	5
both	1	3	4	0.001 ^※
IPSS at baseline
mean ± SD	8.7 ± 6.9	7.2 ± 5.6	8.3 ± 6.6	0.107 ^§
Follow-up period (month)
mean ± SD	44.2 ± 14.9	38.3 ± 16.2	42.5 ± 15.5	0.011 ^§

ISSN: 1748-717X